Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCL-2 inhibition in AML: an unexpected bonus?
Marina Konopleva, Anthony Letai
Blood (2018) Vol. 132, Iss. 10, pp. 1007-1012
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat, et al.
Blood (2018) Vol. 133, Iss. 1, pp. 7-17
Open Access | Times Cited: 1539
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies
Sven Christian, Claudia Merz, Laura Evans, et al.
Leukemia (2019) Vol. 33, Iss. 10, pp. 2403-2415
Open Access | Times Cited: 183
Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response
David Sharon, Séverine Cathelin, Sara Mirali, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 516
Closed Access | Times Cited: 160
Venetoclax-based therapies for acute myeloid leukemia
Veronica Guerra, Courtney D. DiNardo, Marina Konopleva
Best Practice & Research Clinical Haematology (2019) Vol. 32, Iss. 2, pp. 145-153
Open Access | Times Cited: 151
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Faroogh Marofi, Heshu Sulaiman Rahman, Zaid Al-Obaidi, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 113
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Masayuki Yamashita, Paul V. Dellorusso, Oakley C. Olson, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 7, pp. 365-382
Open Access | Times Cited: 132
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, et al.
Cancer Cell (2020) Vol. 38, Iss. 6, pp. 872-890.e6
Open Access | Times Cited: 124
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
Eric S. Winer, Richard M. Stone
Therapeutic Advances in Hematology (2019) Vol. 10
Open Access | Times Cited: 108
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia
Lucie de Beauchamp, Ekaterini Himonas, G. Vignir Helgason
Leukemia (2021) Vol. 36, Iss. 1, pp. 1-12
Open Access | Times Cited: 102
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Salihanur Darici, Hazem Alkhaldi, Gillian Horne, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2934-2934
Open Access | Times Cited: 86
The role of autophagy in targeted therapy for acute myeloid leukemia
Wenxin Du, Aixiao Xu, Yunpeng Huang, et al.
Autophagy (2020) Vol. 17, Iss. 10, pp. 2665-2679
Open Access | Times Cited: 83
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Jan Philipp Bewersdorf, Rory M. Shallis, Maximilian Stahl, et al.
Therapeutic Advances in Hematology (2019) Vol. 10
Open Access | Times Cited: 77
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 10, pp. e756-e765
Closed Access | Times Cited: 60
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Joan Montero, Rizwan Haq
Cancer Discovery (2022) Vol. 12, Iss. 5, pp. 1217-1232
Open Access | Times Cited: 46
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
Sylvain Garciaz, Marie‐Anne Hospital, Anne‐Sophie Alary, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 2025-2025
Open Access | Times Cited: 40
Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
Kateryna Fedorov, Abhishek Maiti, Marina Konopleva
Cancers (2023) Vol. 15, Iss. 8, pp. 2312-2312
Open Access | Times Cited: 23
Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway
Xibao Yu, Yan Wang, Jiaxiong Tan, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 14
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Alexandre Bazinet, Guillermo Garcia‐Manero, Nicholas J. Short, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 4, pp. e276-e286
Closed Access | Times Cited: 12
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
Alexandre Bazinet, Hagop M. Kantarjian, Álex Bataller, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 4, pp. e287-e298
Closed Access | Times Cited: 10
RNA sequestration in P-bodies sustains myeloid leukaemia
Srikanth Kodali, Ludovica Proietti, Gemma Valcárcel, et al.
Nature Cell Biology (2024) Vol. 26, Iss. 10, pp. 1745-1758
Closed Access | Times Cited: 9
Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid Leukemia
Juan Bautista Menendez-Gonzalez, Milica Vukovic, Ali Abdelfattah, et al.
Stem Cell Reports (2019) Vol. 13, Iss. 2, pp. 291-306
Open Access | Times Cited: 65
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
Bachar Samra, Marina Konopleva, Alessandro Isidori, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 64
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia
Johannes Schmoellerl, Inês Amorim Monteiro Barbosa, Thomas Eder, et al.
Blood (2020) Vol. 136, Iss. 4, pp. 387-400
Open Access | Times Cited: 61
Acute Myeloid Leukemia: Aging and Epigenetics
Polina Zjablovskaja, Maria Carolina Florian
Cancers (2019) Vol. 12, Iss. 1, pp. 103-103
Open Access | Times Cited: 57
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Prajwal Dhakal, Melissa L. Bates, Michael H. Tomasson, et al.
Blood Reviews (2022) Vol. 59, pp. 101036-101036
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top